The investigational oral antiviral molnupiravir eliminated actively infectious SARS-CoV-2, improved self-reported outcomes and benefited immunocompromised patients with COVID-19, according to three separate analyses of the MOVe-OUT study.
The European Congress of Clinical Microbiology and Infectious Diseases released the data ahead of its meeting, which is being held later this month. The drug is one of two antivirals that are authorized for the treatment of COVID-19 in the United States. It was developed by Merck in collaboration with Ridgeback Biotherapeutics.
Previous data from the